Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: Evidence based on recent phase III randomized trials

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 2666-2676

  Zhang, Wen Qian ^a   Li, Tong ^a   Li, Hui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Carcinoma; ERBB 1; Genes; Meta Analysis; Non small cell lung

Indexed keywords

AFATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PACLITAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; DIARRHEA; DRUG EFFICACY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FATIGUE; GENE; GENE MUTATION; HAZARD RATIO; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; META ANALYSIS; NAUSEA AND VOMITING; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; MUTATION; TREATMENT OUTCOME;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84917742026     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.892476     Document Type: Article

References (34)

1. Sun S, Schiller JH, Gazdar AF: Lung cancer in never smokers-a different disease. Nat Rev Cancer, 2007; 7: 778-90.
2. Sato M, Shames DS, Gazdar AF et al: A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol, 2007; 2: 327-43.
3. Bozcuk H, Gumus A, Ozbilim G et al: Cluster analysis of p-glycoprotein, cerb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer. Med Sci Monit, 2005; 11(6): HY11-20.
4. Suda K, Mizuuchi H, Maehara Y et al: Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev, 2012; 31: 807-14.
5. Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 2005; 5: 341-54.
6. Flego V, Ristic S, Devic Pavlic S et al: Tumor necrosis factor-alpha gene promoter-308 and-238 polymorphisms in patients with lung cancer as a second primary tumor. Med Sci Monit, 2013; 19: 846-51.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005; 353: 123-32.
8. Dahabreh IJ, Linardou H, Siannis F et al: Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res, 2010; 16: 291-303.
9. Yoshida K, Yatabe Y, Park JY et al: Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol, 2007; 2: 22-28.
10. Rosell R, Moran T, Queralt C et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009; 361: 958-67.
11. Paez JG, Janne PA, Lee JC et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004; 304: 1497-500.
12. Fukuoka M, Wu YL, Thongprasert S et al: Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011; 29: 2866-74.
13. Mitsudomi T, Morita S, Yatabe Y et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010; 11: 121-28.
14. Inoue A, Kobayashi K, Maemondo M et al: Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol, 2013; 24: 54-59.
15. Han JY, Park K, Kim SW et al: First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol, 2012; 30: 1122-28.
16. Zhou C, Wu YL, Chen G et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011; 12: 735-42.
17. Zhou C WY, Liu X et al: Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts), 2012; 30(Suppl.).
18. Rosell R, Carcereny E, Gervais R et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, openlabel, randomised phase 3 trial. Lancet Oncol, 2012; 13: 239-46.
19. Sequist LV, Yang JC, Yamamoto N et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013; 31: 3327-34.
20. Wu YL ZC, Hu CP et al: LUX-Lung 6: A randomized, openlabel, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutationpositive (EGFR M+) advanced adenocarcinoma of the lung. J Clin Oncol (Meeting Abstracts), 2013; 31.
21. Sekine I, Ichinose Y, Nishiwaki Y et al: Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel. Ann Oncol, 2009; 20: 1483-88.
22. Sun JM, Lee KH, Kim SW et al: Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer, 2012; 118: 6234-42.
23. Lee DH, Park K, Kim JH et al: Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res, 2010; 16: 1307-14.
24. Kim ES, Hirsh V, Mok T et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet, 2008; 372: 1809-18.
25. Ciuleanu T, Stelmakh L, Cicenas S et al: Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, nonsmall-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 2012; 13: 300-8.
26. Garassino MC, Bettini A, Floriani I et al: TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR. J Clin Oncol (Meeting Abstracts), 2012; 30.
27. Gregorc V, Novello S, Lazzari C et al: Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol, 2014; 15: 713-21.
28. Karampeazis A, Voutsina A, Souglakos J et al: Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer, 2013; 119: 2754-64.
29. Kawaguchi T, Ando M, Asami K et al: Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second-or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol, 2014; 32: 1902-8.
30. Schiller JH, Harrington D, Belani CP et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002; 346: 92-98.
31. Bir F, Aksoy Altinboga A et al: Potential utility of p63 expression in differential diagnosis of non-small-cell lung carcinoma and its effect on prognosis of the disease. Med Sci Monit, 2014; 20: 219-26.
32. Maemondo M, Inoue A, Kobayashi K et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Engl J Med, 2010; 362: 2380-88.
33. Maruyama R, Nishiwaki Y, Tamura T et al: Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with nonsmall-cell lung cancer. J Clin Oncol, 2008; 26: 4244-52.
34. Hotta K, Kiura K, Fujiwara Y et al: Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PloS One, 2011; 6: e26646.